Jitte Jennekens, MSc, organ perfusionist/transplant coordinator at the UMC Utrecht in the Netherlands, presented the study results at today’s Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) in Boston.
Ex vivo lung perfusion (EVLP) is a technique that allows for donor lungs to be maintained, assessed, and potentially reconditioned outside of the body before transplantation. The lungs are connected to a pump and a ventilator and perfused with a solution that functions as a physiological fluid.
The UMC Utrecht developed its HOPE protocol to safely extend perfusion times, to maintain the viability of the lungs overnight until the transplantation can be performed during the day.
Donor lungs selected for EVLP are typically transported on ice and then warmed to 37 degrees Celsius using a normothermic EVLP (called nEVLP) protocol for functional assessment. Following nEVLP, the lungs are then returned to ice until the transplant begins.
The HOPE protocol eliminates the second period on ice by assessing the lungs during one hour of nEVLP and then preserving the lungs at 12 degrees C until the procedure.
Jennekens presented data comparing the outcomes of 12 cases conducted using the nEVLP-HOPE protocol with a historical cohort of donor lungs transplanted directly into patients without ex vivo lung perfusion.
The control cohort included 118 cases of lungs transplanted directly without perfusion between 2017 and 2022. The cases were performed between 2022 and 2024 using the HOPE protocol for logistical reasons.
No lungs in the nEVLP-HOPE group were rejected for transplantation, and short-term outcomes were similar between the study and control groups.
Jennekens said the next step is to determine the preservation strategy that will be most beneficial to a specific type of donor lung.
27 April 2025, Boston—Researchers at the Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) marked the 10-year anniversary of modern heart donation after circulatory death (DCD), a technique that has significantly increased transplant volumes around the world.
Sarah Scheuer, MD, PhD, said that most centers that have started a DCD program experience an approximately 30 percent increase in their transplant volume.
“It’s arguably the biggest shift in heart transplantation since the introduction of modern immunosuppression,” she said.
In a DCD transplant, the heart comes from a donor whose circulatory and respiratory functions have stopped but who did not meet criteria for brain death.
“The first heart transplants performed in the ‘60s and ‘70s all preceded the legislation surrounding brain death, so in essence, they were DCD,” said Dr. Scheuer, MD, PhD, a cardiothoracic surgeon trainee at St. Vincent’s Hospital in Sydney, Australia.
After brain death criteria were established in 1981, donation after brain death (DBD) was the predominant source of donated hearts for nearly five decades.
The first modern DCD heart transplant was performed at St. Vincent’s Hospital in 2014; the Royal Papworth Hospital in Cambridge, England, followed with their first in 2015. The modern DCD pathway was developed over a 10-year period of research and laboratory work conducted in Australia and the UK, both of which are challenged by the limited availability of donor organs.
In 2022, a randomized, controlled trial in the United States showed that transplantation outcomes with DCD hearts were comparable to traditional (DBD) hearts.
“The successful US trial led to a real explosion of the field within the USA with increasing numbers of centers starting modern DCD heart transplant programs,” Dr. Scheuer said. “It’s a huge impact on the availability of donor hearts.”
Over the past decade, 123 DCD hearts have been transplanted as part of the St. Vincent’s DCD program, and 134 DCD hearts have been transplanted at Royal Papworth Hospital.
“Papworth and St. Vincent's have both had a long history of innovation and research within our heart transplant programs,” said Dr. Scheuer. “We’re always pushing the boundaries, partially out of necessity, and also out of a desire to offer transplantation to more people because, in many ways, it’s the best treatment for end-stage heart failure.”
Dr. Stephen Pettit, a transplant lead and consultant cardiologist at Royal Papworth Hospital, said DCD heart transplantation is gradually spreading worldwide, increasing the use of hearts that otherwise could not have been donated.
“Families of potential organ donors, who must give permission before organs are donated in the UK, have been very supportive of DCD heart transplantation,” Dr. Pettit said. “The DCD process makes sense to families who sometimes struggle with the concept of brain death.”
Researchers are looking for biomarkers to help identify whether DCD hearts are in good condition before transplantation and exploring less costly options for preserving the donor heart (called perfusion) during transportation. A shift toward regenerative medicine is also on the horizon.
“We may get to the point where we put a heart on a perfusion or preservation device and spend the next few hours effectively improving the function of that organ,” said Dr. Scheuer. “I think we'll also get more clarity on the best method of preserving hearts during DCD transplantation.”
For now, she’s gratified by the many lives changed by transplantation, including a St. Vincent patient who received a DBD heart as a teenager and, more recently, a second DCD heart in his 40s.
“We're at a point with heart transplantation where some patients will live a relatively normal duration of life,” she said. “I don't think we have any other treatment for heart failure that can offer that potential outcome.”
END
Technology Could Pave the Way to International Heart Exchange
27 April 2025, Boston—In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn’t get the organ to a recipient in time.
“If there isn’t a recipient for an available heart in Perth but there’s a match in Sydney, that's nearly 2,000 miles of travel, or a five-hour flight,” said Emily Granger, MBBS, cardiothoracic and heart and lung transplant surgeon at St. Vincent's Hospital, Sydney, Australia. “Add to that a couple of hours for retrieval and preparation, and that’s a seven-hour journey.”
Dr. Granger addressed organ transportation time at today’s Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) in Boston.
“We’ve focused much of our research at St. Vincent's on ensuring that we can protect and preserve the donor heart not only for a long distance but also for a long time,” she said.
Until recently, donor hearts had to be transported in a portable cooler, which gave transplant teams six hours to get a donor heart implanted. The inception of machine perfusion, in which a device pumps a blood-like solution through the donor heart during transport, has significantly extended that window.
St. Vincent’s, a pioneer of machine perfusion, began using the technology in 2014 for hearts donated following circulatory death (DCD). Today, machine perfusion is used in over half of the center’s heart transplants.
“We recognized that we needed a system that would enable us to span the country,” she said. “We knew we had to remove time from the equation.”
St. Vincent has pushed the limits of normothermic machine perfusion (NMP), in which the heart is perfused and preserved at approximately 35 degrees Celsius, for up to 8 hours. Other Australian units have even used the system for 10 hours.
“Ten years ago, we had to refuse donor organs because of time constraints,” she said. “Now we can accept organs from regions we never thought were possible and be confident they’ll work.”
She said in the near future, it may be possible to push the boundaries even more.
“We could actually look at an international exchange of donor hearts to allow transport between countries,” she said.
Australia already retrieves donor organs from New Zealand; however, machine perfusion could allow transplantation teams to travel to the Pacific Islands and Asia.
“There are a significant number of patients on our transplant list that are very difficult to match to a donor,” she said. “The answer for them could be a donor from a slightly different genetic population than we have in our local area. Their ideal donor might actually live in a different country.”
Research conducted at St. Vincent’s has shown that outcomes for heart transplants involving machine perfusion are comparable to transplants performed without it.
“We looked specifically at the primary graft function in the transplanted heart and found no difference across modalities,” she said. “We like to think that we're removing the impact of time by using machine perfusion.”
Dr. Granger said the technology represents a true sea change for heart transplant teams.
“When I began my career as a transplant surgeon, we just had a portable cooler,” she said. “The space has totally transformed, and the only thing limiting us at the moment is our imagination.”
END
The ISHLT Annual Meeting and Scientific Sessions will be held from 27-30 April at the John B. Hynes Veterans Memorial Convention Center in Boston.